title: Treatment of primary intraocular lymphoma with radiation therapy: a multi-institutional survey in Japan.
abstract: This study evaluated the clinical features and treatment outcome of 15 patients with primary intraocular lymphoma. There were nine females, with a median age of 68 years. Thirteen patients presented with bilateral lesions and median time from the onset of symptoms to diagnosis was 12 months. All but one showed the B-cell phenotype. All patients received radiation therapy (RT) with a median of 41 Gy and 10 were administered chemotherapy as well. Three patients were treated with high-dose methotrexate and nine received prophylactic cranial irradiation (PCI) with a median of 30.6 Gy. Thirteen patients obtained a complete remission. The 2-year overall and disease free survival were 74% and 58%, respectively. Although only one patient experienced local recurrence, PCI did not prevent intracranial recurrence. One patient developed a grade 3 cognitive disturbance. It was concluded that ocular RT was effective to control primary lesions. However, some modifications are indispensable to improve outcomes.
authors.affiliation: Japanese Society for Therapeutic Radiology and Oncology Study Group, and Department of Radiology, Chiba University Hospital, 1-8-01 Inohana, Chuo-ku, Chiba 260-8677, Japan. isobeko@ho.chiba-u.ac.jp
authors.forename: Koichi
authors.initials: K
authors.lastname: Isobe
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ejima
authors.forename: Sunao
authors.initials: S
authors.lastname: Tokumaru
authors.forename: Naoto
authors.initials: N
authors.lastname: Shikama
authors.forename: Gen
authors.initials: G
authors.lastname: Suzuki
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Takemoto
authors.forename: Emiko
authors.initials: E
authors.lastname: Tsuchida
authors.forename: Miwako
authors.initials: M
authors.lastname: Nomura
authors.forename: Yuta
authors.initials: Y
authors.lastname: Shibamoto
authors.forename: Naofumi
authors.initials: N
authors.lastname: Hayabuchi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005134:Eye Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy*; D005260:Female; D006306:Health Surveys; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008223:Lymphoma / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate